Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight LossGlobeNewsWire • 10/01/26
Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to WinZacks Investment Research • 10/01/26
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology AntibodiesGlobeNewsWire • 10/01/26
Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodiesGlobeNewsWire • 10/01/26
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026GlobeNewsWire • 09/24/26
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum TranscriptSeeking Alpha • 09/23/26
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 09/15/26
Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts and EYLEA HD MomentumMarketBeat • 09/15/26
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/15/26
REGN DEADLINE ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. Investors to Today's September 14, 2026 Lead Plaintiff Deadline in Securities Class ActionPRNewsWire • 09/14/26
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Regeneron (REGN) Investors of Securities Class Action Lawsuit Deadline on September 14, 2026Business Wire • 09/14/26
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS LawBusiness Wire • 09/14/26